Johansson C J, Teder H, Grönquist L, Gunnarsson P O
Kabi Pharmacia AB, Therapeutics Oncology Dept. of Pharmacokinetics, Helsingborg, Sweden.
Acta Oncol. 1994;33(1):39-42. doi: 10.3109/02841869409098373.
Urinary concentration of doxorubicin and its active metabolite doxorubicinol was followed in two groups of rats after hepatic intra-arterial injection of a single dose of 6 mg/kg doxorubicin or the same dose combined with 30 mg/kg Spherex (DSM). Urinary samples were collected during five days following administration. The concomitant DSM administration caused a significant decrease of the cumulative urinary excretion of intact doxorubicin; average five days of cumulative values were 73 and 103 micrograms respectively in the group with and without DSM. This indicates a DSM-induced reduction in systemic drug exposure. The elimination rates of doxorubicin or its active metabolite were not influenced by DSM. The decrease in excretion of the parent drug was not due to an interaction between the drug and DSM as evident by examining the binding of doxorubicin to DSM in vitro. Instead regionally altered drug distribution seems a plausible explanation to the reduction.
在两组大鼠经肝动脉注射单剂量6mg/kg阿霉素或相同剂量阿霉素与30mg/kg Spherex(帝斯曼公司)联合用药后,对其尿液中阿霉素及其活性代谢物阿霉素醇的浓度进行了跟踪监测。给药后五天内收集尿液样本。同时给予Spherex导致完整阿霉素的累积尿排泄量显著降低;在有和没有Spherex的组中,五天的平均累积值分别为73和103微克。这表明Spherex可降低全身药物暴露。阿霉素或其活性代谢物的消除率不受Spherex影响。通过体外检测阿霉素与Spherex的结合情况可知,母体药物排泄减少并非由于药物与Spherex之间的相互作用。相反,区域药物分布改变似乎是排泄减少的一个合理原因。